Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
Add more filters










Publication year range
1.
Protoplasma ; 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38864933

ABSTRACT

Microalgae are considered promising sustainable sources of natural bioactive compounds to be used in biotechnological sectors. In recent years, attention is increasingly given to the search of microalgae-derived compounds with antioxidant and anti-inflammatory properties for nutraceutical or pharmacological issues. In this context, attention is usually focused on the composition and bioactivity of algae or their extracts, while less interest is driven to their biological features, for example, those related to morphology and cultivation conditions. In addition, specific studies on the antioxidant and anti-inflammatory properties of microalgae mainly concern Chlorella or Spirulina. The present work was focused on the characterization of the Chlorophyta Neochloris oleoabundans under two combinations of cultivation modes: autotrophy and glucose-induced mixotrophy, each followed by starvation. Biomass for morphological and biochemical characterization, as well as for extract preparation, was harvested at the end of each cultivation phase. Analyses indicated a different content of the most important classes of bioactive compounds with antioxidant/anti-inflammatory properties (lipids, exo-polysaccharides, pigments, total phenolics, and proteins). In particular, the most promising condition able to prompt the production of antioxidant algal biomass with anti-inflammatory properties was the mixotrophic one. Under mixotrophy, beside an elevated algal biomass production, a strong photosynthetic metabolism with high appression of thylakoid membranes and characteristics of high photo-protection from oxidative damage was observed and linked to the overproduction of exo-polysaccharides and lipids rather than pigments. Overall, mixotrophy appears a good choice to produce natural bioactive extracts, potentially well tolerated by human metabolism and environmentally sustainable.

2.
Curr Med Chem ; 17(30): 3488-502, 2010.
Article in English | MEDLINE | ID: mdl-20738250

ABSTRACT

Adenosine is an important autocoid, exerting its physiological effects on the human body by activation of four different G-protein-coupled-receptors (GPCRs) classified as A(1), A(2A), A(2B), and A(3). These receptors are coupled to secondary messenger systems including adenylate cyclase, inositol phosphate metabolism, and K(+), K(ATP) and Ca(2+) channels. Pharmacological agents that increase the activation of A(1) adenosine receptors in response to adenosine would be useful for treatment of cardiovascular, central nervous system, and inflammatory pathologies. Compounds that are able to enhance the activity of the A(1)-adenosine receptors by the endogenous ligand within specific tissues may have potential therapeutic advantages over non-endogenous agonists. Such an opportunity for intervention is provided by the concept of allosteric modulation of GPCRs. Therefore the use of allosteric enhancers to increase the responsiveness of the A(1) receptors to endogenous adenosine at sites of its production is an appealing alternative to activation by exogenous agonists. This approach minimizes side effects because allosteric enhancers amplify the action of the agonist by stabilizing the agonist-A(1)-receptor-G protein ternary complex. The allosteric enhancement of the GABA(A) receptor by benzodiazepines is the most famous and successful example of this strategy. The aim of this article is to give an overview of the results obtained in this field and discuss the opportunities and challenges that this class of ligands might offer for medicinal chemistry and pharmacology.


Subject(s)
Receptor, Adenosine A1/chemistry , Allosteric Regulation , Humans , Receptor, Adenosine A1/metabolism , Thiazoles/chemistry , Thiazoles/pharmacology , Thiophenes/chemistry , Thiophenes/pharmacology
3.
Handb Exp Pharmacol ; (193): 297-327, 2009.
Article in English | MEDLINE | ID: mdl-19639286

ABSTRACT

The study of the A(3) adenosine receptor (A(3)AR) represents a rapidly growing and intense area of research in the adenosine field. The present chapter will provide an overview of the expression patterns, molecular pharmacology and functional role of this A(3)AR subtype under pathophysiological conditions. Through studies utilizing selective A(3)AR agonists and antagonists, or A(3)AR knockout mice, it is now clear that this receptor plays a critical role in the modulation of ischemic diseases as well as in inflammatory and autoimmune pathologies. Therefore, the potential therapeutic use of agonists and antagonists will also be described. The discussion will principally address the use of such compounds in the treatment of brain and heart ischemia, asthma, sepsis and glaucoma. The final part concentrates on the molecular basis of A(3)ARs in autoimmune diseases such as rheumatoid arthritis, and includes a description of clinical trials with the selective agonist CF101. Based on this chapter, it is evident that continued research to discover agonists and antagonists for the A(3)AR subtype is warranted.


Subject(s)
Receptor, Adenosine A3/physiology , Animals , Autoimmune Diseases/etiology , Brain Ischemia/etiology , Humans , Inflammation/etiology , Myocardial Ischemia/etiology , Receptor, Adenosine A3/drug effects , Receptor, Adenosine A3/genetics , Signal Transduction
4.
Handb Exp Pharmacol ; (193): 399-441, 2009.
Article in English | MEDLINE | ID: mdl-19639290

ABSTRACT

The A(1), A(2A), A(2B) and A(3) G-protein-coupled cell surface adenosine receptors (ARs) are found to be upregulated in various tumor cells. Activation of the receptors by specific ligands, agonists or antagonists, modulates tumor growth via a range of signaling pathways. The A(1)AR was found to play a role in preventing the development of glioblastomas. This antitumor effect of the A(1)AR is mediated via tumor-associated microglial cells. Activation of the A(2A)AR results in inhibition of the immune response to tumors via suppression of T regulatory cell function and inhibition of natural killer cell cytotoxicity and tumor-specific CD4+/CD8+ activity. Therefore, it is suggested that pharmacological inhibition of A(2A)AR activation by specific antagonists may enhance immunotherapeutics in cancer therapy. Activation of the A(2B)AR plays a role in the development of tumors via upregulation of the expression levels of angiogenic factors in microvascular endothelial cells. In contrast, it was evident that activation of A(2B)AR results in inhibition of ERK1/2 phosphorylation and MAP kinase activity, which are involved in tumor cell growth signals. Finally, A(3)AR was found to be highly expressed in tumor cells and tissues while low expression levels were noted in normal cells or adjacent tissue. Receptor expression in the tumor tissues was directly correlated to disease severity. The high receptor expression in the tumors was attributed to overexpression of NF-kappaB, known to act as an A(3)AR transcription factor. Interestingly, high A(3)AR expression levels were found in peripheral blood mononuclear cells (PBMCs) derived from tumor-bearing animals and cancer patients, reflecting receptor status in the tumors. A(3)AR agonists were found to induce tumor growth inhibition, both in vitro and in vivo, via modulation of the Wnt and the NF-kappaB signaling pathways. Taken together, A(3)ARs that are abundantly expressed in tumor cells may be targeted by specific A(3)AR agonists, leading to tumor growth inhibition. The unique characteristics of these A(3)AR agonists make them attractive as drug candidates.


Subject(s)
Neoplasms/etiology , Receptors, Purinergic P1/physiology , Adenosine A2 Receptor Antagonists , Adenosine A3 Receptor Antagonists , Animals , Antineoplastic Agents/pharmacology , Humans , Immunotherapy , NF-kappa B/physiology , Neoplasms/immunology , Receptor, Adenosine A1/physiology , Receptor, Adenosine A2A/physiology , Receptor, Adenosine A2B/physiology , Receptor, Adenosine A3/physiology , Signal Transduction , Wnt Proteins/physiology
5.
Osteoarthritis Cartilage ; 16(11): 1421-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18448363

ABSTRACT

OBJECTIVE: The aim of the present study is that of characterizing, for the first time in a quantitative way, from a biochemical, physico chemical and functional point of view P2X(1) and P2X(3) purinergic receptors in bovine chondrocytes. The affinity and the potency of typical purinergic ligands were studied through competition binding experiments and their role in modulating chondrocyte actvities was investigated by analyzing nitric oxide (NO) and prostaglandin E2 (PGE(2)) release. METHODS: Saturation, competition binding experiments, western blotting and immunohistochemistry assays on the P2X(1) and P2X(3) purinergic receptors in bovine chondrocytes were performed. Thermodynamic analysis of the P2X(1) and P2X(3) purinergic binding was studied to investigate the forces driving drug-receptor coupling. In the functional assays (NO and PGE(2) release) the potency of purinergic agonists and antagonists was evaluated. RESULTS: Bovine chondrocytes expressed P2X(1) and P2X(3) purinergic receptors and thermodynamic parameters indicated that purinergic binding is enthalpy- and entropy-driven for agonists and totally entropy-driven for antagonists. Typical purinergic agonists such as adenosine 5'-triphosphate (ATP) and alpha,beta-methyleneATP were able to increase NO and PGE(2) release. A purinergic antagonist, A317491, was able to block the stimulatory effect on functional experiments mediated by the agonists. CONCLUSIONS: These data demonstrate for the first time the presence of functional P2X(1) and P2X(3) purinergic receptors in bovine chondrocytes. Agonists and antagonists are thermodynamically discriminated and are able to modulate functional responses such as NO and PGE(2) release. These results suggest the potential role of novel purinergic antagonists in the treatment of pathophysiological diseases linked to the inflammation and involved in articular cartilage resorption.


Subject(s)
Chondrocytes/metabolism , Dinoprostone/metabolism , Nitric Oxide/metabolism , Receptors, Purinergic P2/metabolism , Animals , Binding, Competitive , Biomarkers/metabolism , Cattle , Cells, Cultured , Receptors, Purinergic P2X , Receptors, Purinergic P2X3
6.
Osteoarthritis Cartilage ; 16(3): 292-304, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17698373

ABSTRACT

OBJECTIVE: The present study describes the presence and binding parameters of the A1, A2A, A2B and A3 adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes. The effect of low frequency low energy pulsed electromagnetic fields (PEMFs) on the adenosine receptor affinity and density was studied. METHODS: Saturation, competition binding experiments and Western blotting assays in the absence and in the presence of PEMFs on the adenosine receptors in bovine chondrocytes or fibroblast-like synoviocytes were performed. Thermodynamic analysis of the A2A or A3 binding was studied to investigate the forces driving drug-receptor coupling. In the adenylyl cyclase and proliferation assays the potency of typical high-affinity A2A or A3 agonists in the absence and in the presence of PEMFs was evaluated. RESULTS: Bovine chondrocytes and fibroblast-like synoviocytes expressed all adenosine receptors. PEMFs evoked an up-regulation of A2A and A3 receptors and thermodynamic parameters indicate that adenosine binding is enthalpy and entropy driven. In PEMF-treated cells the potency of typical A2A or A3 agonists on cyclic AMP assays was significantly increased when compared with the untreated cells. PEMFs potentiated the effect of A2A or A3 agonists on cell proliferation in both cell types. CONCLUSIONS: PEMFs mediate an up-regulation of A2A and A3 receptors related to an increase of their functional activities in bovine chondrocytes and fibroblast-like synoviocytes. No differences are present in adenosine affinity and in the drug-receptor interactions. Our data could be used as a trigger to future studies addressed to PEMFs and adenosine therapeutic intervention in inflammatory joint diseases.


Subject(s)
Binding, Competitive/physiology , Chondrocytes/metabolism , Electromagnetic Fields , Receptors, Purinergic P1/metabolism , Synovial Fluid/cytology , Thermodynamics , Animals , Arthritis/physiopathology , Arthritis/therapy , Blotting, Western , Cattle , Cell Proliferation , Cells, Cultured , Chondrocytes/chemistry , Chondrocytes/cytology , Cyclic AMP/metabolism , Data Interpretation, Statistical , Fibroblasts , In Vitro Techniques , Phenotype , Purinergic P1 Receptor Agonists , Receptors, Purinergic P1/analysis , Synovial Fluid/chemistry , Synovial Fluid/metabolism , Temperature , Up-Regulation
7.
Cell Mol Life Sci ; 62(19-20): 2350-8, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16143823

ABSTRACT

Caffeine is the most widely used drug in the world and acts mainly through antagonism of the effects mediated by the adenosine receptor subtypes A1, A2A, A2B and A3. We determined whether repeated caffeine administration at different doses and for different periods of time (400 or 600 mg/day for 1 week and 400 mg/day for 2 weeks) alters human neutrophil A2A adenosine receptor density and function. Saturation binding assays showed an increase in affinity (K(D)) and density (B(max)) of A2A adenosine receptors after caffeine intake. These changes were accompanied by increases in cAMP accumulation and decreases in superoxide anion production after stimulation of the A2A receptor subtype using the agonist 5'-N-ethylcarboxamidoadenosine (NECA). Binding and functional changes of A2A receptors returned to baseline after 48 h of caffeine withdrawal. The findings are consistent with a potential anti-inflammatory effect of caffeine mediated by neutrophil A2A receptors.


Subject(s)
Caffeine/pharmacology , Neutrophils/drug effects , Receptor, Adenosine A2A/metabolism , Adenosine A2 Receptor Agonists , Adenosine-5'-(N-ethylcarboxamide)/pharmacology , Adult , Cells, Cultured , Cyclic AMP/metabolism , Humans , Male , Neutrophils/metabolism , Superoxides/metabolism
8.
Naunyn Schmiedebergs Arch Pharmacol ; 367(2): 109-18, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12595951

ABSTRACT

Two mechanisms are responsible for the positive inotropic effect of the cardiotonic drug milrinone, i.e., inhibition of type III cAMP phosphodiesterase (PDE III), and displacement of endogenous adenosine from A(1) inhibitory receptor. Since PDE III inhibition may increase the likelihood of cardiac arrhythmias by increasing cAMP content, our attention focused on the synthesis of new compounds with more pronounced characteristics as adenosine antagonists. In this work, four new milrinone analogues were studied, in comparison with the parent drug, for their effects on the contractility of guinea pig isolated atrial preparations, their ability to antagonize endogenous adenosine at the level of A(1) receptor, and to inhibit the activity of PDE III partially purified from guinea pig heart. The new compounds present various chemical substitutions with respect to the parent drug: in compounds SF397 (methyl 5-cyano-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate) and SF399 (benzyl 5-cyano-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate), the 4-pyridil moiety of milrinone was replaced with a methoxycarbonyl and a benzyloxycarbonyl group, respectively; the same structural modifications were also associated with the replacement of the cyano-group in 5-position with an acetyl group in compounds SF416 (methyl 5-acetyl-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate) and SF419 (benzyl 5-acetyl-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate). All the new compounds had a marked positive inotropic effect, most of them also being more active and more potent than milrinone. When their affinity for A(1) receptor was assessed as the displacement of [(3)H] 8-cyclopentyl-1,3-dipropylxanthine ([(3)H]DPCPX) from cardiac membranes, SF397 and SF399 showed affinity (K(i) of about 600 nM) similar to that of milrinone (K(i) 550 nM). By contrast, SF416 and SF419 had very low (K(i) of about 10000 nM) or scarce (K(i) of about 2000 nM) anti-adenosine component, respectively. All the new compounds inhibited PDE III activity, their K(i) values proceeding in the following order: milrinone (3.80 microM)

Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Adenosine A1 Receptor Antagonists , Milrinone/analogs & derivatives , Milrinone/pharmacology , Myocardial Contraction/drug effects , Phosphodiesterase Inhibitors/pharmacology , Animals , Calcium/metabolism , Calcium-Transporting ATPases/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 3 , Guinea Pigs , Heart Atria/drug effects , In Vitro Techniques , Male , Receptors, Adrenergic, beta/drug effects , Sodium-Calcium Exchanger/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Stimulation, Chemical , Structure-Activity Relationship
9.
Br J Pharmacol ; 134(6): 1215-26, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11704641

ABSTRACT

1. The present work characterizes, from a pharmacological and biochemical point of view, adenosine receptors in the human malignant melanoma A375 cell line. 2. Adenosine receptors were detected by RT - PCR experiments. A1 receptors were characterized using [3H]-DPCPX binding with a KD of 1.9+/-0.2 nM and Bmax of 23+/-7 fmol x mg(-1) of protein. A2A receptors were studied with [3H]-SCH 58261 binding and revealed a KD of 5.1+/-0.2 nM and a Bmax of 220+/-7 fmol x mg(-1) of protein. A3 receptors were studied with the new A3 adenosine receptor antagonist [3H]-MRE 3008F20, the only A3 selective radioligand currently available. Saturation experiments revealed a single high affinity binding site with KD of 3.3+/-0.7 nM and Bmax of 291+/-50 fmol x mg(-1) of protein. 3. The pharmacological profile of radioligand binding on A375 cells was established using typical adenosine ligands which displayed a rank order of potency typical of the different adenosine receptor subtype. 4. Thermodynamic data indicated that radioligand binding to adenosine receptor subtypes in A375 cells was entropy- and enthalpy-driven. 5. In functional assays the high affinity A2A agonists HE-NECA, CGS 21680 and A2A - A2B agonist NECA were able to increase cyclic AMP accumulation in A375 cells whereas A3 agonists Cl-IB-MECA, IB-MECA and NECA were able to stimulate Ca2+ mobilization. In conclusion, all these data indicate, for the first time, that adenosine receptors with a pharmacological and biochemical profile typical of the A1, A2A, A2B and A3 receptor subtype are present on A375 melanoma cell line.


Subject(s)
Melanoma, Experimental/metabolism , Phenylurea Compounds/pharmacology , Purinergic P1 Receptor Antagonists , Pyrimidines/pharmacology , Skin Neoplasms/metabolism , Triazoles/pharmacology , Xanthines/pharmacology , Adenosine Deaminase/metabolism , Binding, Competitive , Calcium/metabolism , Cell Membrane/metabolism , Cyclic AMP/metabolism , Humans , Phenylurea Compounds/chemistry , Pyrimidines/chemistry , Radioligand Assay , Receptors, Purinergic P1/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Triazoles/chemistry , Tritium , Tumor Cells, Cultured , Xanthines/chemistry
10.
J Med Chem ; 44(17): 2735-42, 2001 Aug 16.
Article in English | MEDLINE | ID: mdl-11495585

ABSTRACT

A series of pyrazolotriazolopyrimidines was previously reported to be highly potent and selective human A(3) adenosine receptor antagonists (Baraldi et al. J. Med. Chem. 2000, 43, 4768-4780). A derivative having a methyl group at the N(8) pyrazole combined with a 4-methoxyphenylcarbamoyl moiety at N(5) position, displayed a K(i) value at the hA(3) receptor of 0.2 nM. We now describe chemically reactive derivatives which act as irreversible inhibitors of this receptor. Electrophilic groups, specifically sulfonyl fluoride and nitrogen mustard (bis-(beta-chloroethyl)amino) moieties, have been incorporated at the 4-position of the aryl urea group. Membranes containing the recombinant hA(3) receptor were preincubated with the compounds and washed exhaustively. The loss of ability to bind radioligand following this treatment indicated irreversible binding. The most potent compound in irreversibly binding to the receptor was 14, which contained a sulfonyl fluoride moiety and a propyl group at the N(8) pyrazole nitrogen. The bis-(beta-chloroethyl)amino derivatives displayed a much smaller degree of irreversible binding than the sulfonyl fluoride derivatives. A computer-generated model of the human A(3) receptor was built and analyzed to help interpret these results. The model of the A(3) transmembrane region was derived using primary sequence comparison, secondary structure predictions, and three-dimensional homology building, using the recently published crystal structure of rhodopsin as a template. According to our model, sulfonyl fluoride derivatives could dock within the hypothetical TM binding domain, adopting two different energetically favorable conformations. We have identified two amino acids, Ser247 and Cys251, both in TM6, as potential nucleophilic partners of the irreversible binding to the receptor.


Subject(s)
Aniline Compounds/chemical synthesis , Heterocyclic Compounds, 3-Ring/chemical synthesis , Phenylurea Compounds/chemical synthesis , Purinergic P1 Receptor Antagonists , Pyrimidines/chemical synthesis , Aniline Compounds/chemistry , Aniline Compounds/metabolism , Animals , Binding, Competitive , Cell Line , Cricetinae , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/metabolism , Humans , Models, Molecular , Phenylurea Compounds/chemistry , Phenylurea Compounds/metabolism , Pyrimidines/chemistry , Pyrimidines/metabolism , Radioligand Assay , Receptor, Adenosine A3 , Receptors, Purinergic P1/metabolism , Recombinant Proteins/metabolism , Structure-Activity Relationship , Transfection
11.
Br J Pharmacol ; 134(1): 116-26, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11522603

ABSTRACT

1. The present work was devoted to the study of A3 adenosine receptors in Jurkat cells, a human leukemia line. 2. The A3 subtype was found by means of RT-PCR experiments and characterized by using the new A3 adenosine receptor antagonist [3H]-MRE 3008F20, the only A3 selective radioligand currently available. Saturation experiments revealed a single high affinity binding site with K(D) of 1.9+/-0.2 nM and B(max) of 1.3+/-0.1 pmol mg(-1) of protein. 3. The pharmacological profile of [3H]-MRE 3008F20 binding on Jurkat cells was established using typical adenosine ligands which displayed a rank order of potency typical of the A3 subtype. 4. Thermodynamic data indicated that [3H]-MRE 3008F20 binding to A3 subtype in Jurkat cells was entropy- and enthalpy-driven, according with that found in cells expressing the recombinant human A3 subtype. 5. In functional assays the high affinity A3 agonists Cl-IB-MECA and IB-MECA were able to inhibit cyclic AMP accumulation and stimulate Ca(2+) release from intracellular Ca(2+) pools followed by Ca(2+) influx. 6. The presence of the other adenosine subtypes was investigated in Jurkat cells. A1 receptors were characterized using [3H]-DPCPX binding with a K(D) of 0.9+/-0.1 nM and B(max) of 42+/-3 fmol mg(-1) of protein. A2A receptors were studied with [3H]-SCH 58261 binding and revealed a K(D) of 2.5+/-0.3 nM and a B(max) of 1.4+/-0.2 pmol mg(-1) of protein. 7. In conclusion, by means of the first antagonist radioligand [3H]-MRE 3008F20 we could demonstrate the existence of functional A3 receptors on Jurkat cells.


Subject(s)
Receptors, Purinergic P1/genetics , T-Lymphocytes/metabolism , Animals , Binding, Competitive/drug effects , CHO Cells , Calcium/metabolism , Cricetinae , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Guanosine Triphosphate/pharmacology , Humans , Jurkat Cells , Kinetics , Phenylurea Compounds/metabolism , Phenylurea Compounds/pharmacology , Purinergic P1 Receptor Agonists , Pyrimidines/metabolism , Pyrimidines/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor, Adenosine A2A , Receptor, Adenosine A3 , Receptors, Purinergic P1/metabolism , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Thermodynamics , Time Factors , Triazoles/metabolism , Triazoles/pharmacology , Tritium , Xanthines/metabolism , Xanthines/pharmacology
12.
Bioorg Med Chem Lett ; 11(6): 823-7, 2001 Mar 26.
Article in English | MEDLINE | ID: mdl-11277529

ABSTRACT

6-Methoxylated and 8-oxygenated benztropines were prepared and evaluated for their DAT and SERT activity (binding and uptake inhibition). Methoxylation at the two-carbon bridge of benztropine produced a novel class of potent and selective DAT ligands. An interesting enantioselectivity was also observed for this new class of chiral benztropines. The inactivity of the 8-oxygenated analogues seems to point out that, unlike cocaine and its analogues, interactions of benztropine ligands with DAT may be strongly governed by the nitrogen atom.


Subject(s)
Benztropine/pharmacology , Carrier Proteins/metabolism , Membrane Glycoproteins , Membrane Transport Proteins , Muscarinic Antagonists/pharmacology , Nerve Tissue Proteins , Benztropine/chemistry , Carrier Proteins/drug effects , Dopamine Plasma Membrane Transport Proteins , Ligands , Molecular Conformation , Muscarinic Antagonists/chemistry , Structure-Activity Relationship
13.
Eur J Med Chem ; 36(11-12): 873-86, 2001.
Article in English | MEDLINE | ID: mdl-11755230

ABSTRACT

This work reports the synthesis by microwave irradiation and the binding tests on the 5-HT(1A), 5-HT(2A) and 5-HT(2C) receptors of new substituted piperazines in order to identify selective ligands for 5-HT(1A) subtype receptor. Conventional heating and microwave irradiation of the reactions was compared. Synthesis by microwave irradiation gave the desired compounds in better yields than those obtained by conventional heating. The overall times for the syntheses were considerably reduced. Some resulting active compounds (29 and 39) were characterised by a good selectivity profile for the 5-HT(1A) subtype receptor. The more active compounds were selected and further evaluated for their binding affinities on D(1), D(2) dopaminergic and alpha(1), alpha(2) adrenergic receptors. The compound with higher affinity and selectivity for the 5-HT(1A) over all the considered receptors was the 3-[4-[4-(1,2,3,4-tetrahydronaphthyl)-1-piperazinyl]butan]-benzotriazinone (-)29 (5-HT(1A) K(i)=36 nM, other receptors not active).


Subject(s)
Microwaves , Piperazines/chemical synthesis , Receptors, Serotonin/metabolism , Serotonin Antagonists/chemical synthesis , Triazines/chemical synthesis , Animals , Binding Sites , Cerebral Cortex , Ligands , Male , Piperazines/chemistry , Piperazines/pharmacology , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT2A , Receptor, Serotonin, 5-HT2C , Receptors, Serotonin/drug effects , Receptors, Serotonin, 5-HT1 , Serotonin Antagonists/chemistry , Serotonin Antagonists/pharmacology , Triazines/chemistry , Triazines/pharmacology
14.
J Med Chem ; 43(25): 4768-80, 2000 Dec 14.
Article in English | MEDLINE | ID: mdl-11123985

ABSTRACT

An enlarged series of pyrazolotriazolopyrimidines previously reported, in preliminary form (Baraldi et al. J. Med. Chem. 1999, 42, 4473-4478), as highly potent and selective human A(3) adenosine receptor antagonists is described. The synthesized compounds showed A(3) adenosine receptor affinity in the sub-nanomolar range and high levels of selectivity evaluated in radioligand binding assays at human A(1), A(2A), A(2B), and A(3) adenosine receptors. In particular, the effect of the chain at the N(8) pyrazole nitrogen was analyzed. This study allowed us to identify the derivative with the methyl group at the N(8) pyrazole combined with the 4-methoxyphenylcarbamoyl moiety at the N(5) position as the compound with the best binding profile in terms of both affinity and selectivity (hA(3) = 0.2 nM, hA(1)/hA(3) = 5485, hA(2A)/hA(3) = 6950, hA(2B)/hA(3) = 1305). All the compounds proved to be full antagonists in a specific functional model where the inhibition of cAMP generation by IB-MECA was measured in membranes of CHO cells stably transfected with the human A(3) receptor. The new compounds are among the most potent and selective A(3) antagonists so far described. The derivatives with higher affinity at human A(3) adenosine receptors proved to be antagonists, in the cAMP assay, capable of inhibiting the effect of IB-MECA with IC(50) values in the nanomolar range, with a trend strictly similar to that observed in the binding assay. Also a molecular modeling study was carried out, with the aim to identify possible pharmacophore maps. In fact, a sterically controlled structure-activity relationship was found for the N(8) pyrazole substituted derivatives, showing a correlation between the calculated molecular volume of pyrazolo[4,3-e]1,2, 4-triazolo[1,5-c]pyrimidine derivatives and their experimental K(i) values.


Subject(s)
Purinergic P1 Receptor Antagonists , Pyrazoles/chemistry , Pyrimidines/chemical synthesis , Animals , CHO Cells , Cricetinae , Cyclic AMP/biosynthesis , Humans , Models, Molecular , Molecular Structure , Pyrimidines/chemistry , Pyrimidines/pharmacology , Radioligand Assay , Receptor, Adenosine A3 , Structure-Activity Relationship
15.
J Med Chem ; 43(15): 2805-13, 2000 Jul 27.
Article in English | MEDLINE | ID: mdl-10956188

ABSTRACT

Three series of nociceptin (NC)-related peptides were synthesized and their abilities (i) to bind to the NC sites expressed in mouse forebrain membranes, (ii) to inhibit the electrically evoked contraction of the mouse vas deferens, and (iii) to inhibit forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human recombinant NC receptor (CHONCR) were investigated. The compounds of the first series (a series) have an ordinary Xaa1-Gly2 bond, those of the second series (b series) have a Xaa1psi(CH2-NH)Gly2 pseudopeptide bond, and those of the third series (c series) have a peptoid (Nxaa1-Gly2) structure. The affinity values measured in the binding assay and in the two functional assays with the compounds of the three series showed high levels of correlation. Thus, (I) the compounds of the a series in which Phe1 was substituted with Tyr, Cha, or Leu acted as potent NC receptor agonists; (II) the b series compounds behaved as NC receptor antagonists in the mouse vas deferens and as full agonists in CHO(NCR) cells with different potencies depending on the first amino acid residue, [Phe1psi(CH2-NH)Gly2]NC(1-17)NH2 and [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 being the most potent compounds; (III) the compounds of the third series were all inactive both as agonists and as antagonists with the exception of [Nphe1]NC(1-17)NH2 and [Nphe1]NC(1-13)NH2, which behaved as NC receptor antagonists both in the isolated tissue and in CHO(NCR) cells (pKB 6.1-6.4). In conclusion, this study demonstrates that chemical requirements for NC receptor agonists are different from those of antagonists. Moreover, modifications of the steric orientation of the aromatic residue Phe1 in the NC sequence as obtained with the pseudopeptide bond between Phe1 and Gly2 or with the displacement of the benzyl side chain by one atom, as in Nphe1, lead respectively to reduction or elimination of efficacy. Indeed, in contrast to [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 which has been reported to exhibit agonist activity in several assays involving either central or recombinant NC receptors, [Nphe1]NC(1-13)NH2 antagonizes the effect of NC at human recombinant NC receptors and in the mouse tail withdrawal assay.


Subject(s)
Narcotic Antagonists , Opioid Peptides/chemistry , Peptides/chemical synthesis , Animals , Brain/metabolism , CHO Cells , Cricetinae , Cyclic AMP/metabolism , Humans , In Vitro Techniques , Ligands , Male , Mice , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Peptides/chemistry , Peptides/metabolism , Peptides/pharmacology , Peptoids , Protein Binding , Receptors, Opioid/agonists , Recombinant Proteins/chemical synthesis , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Structure-Activity Relationship , Vas Deferens/drug effects , Vas Deferens/physiology , Nociceptin Receptor , Nociceptin
16.
Circulation ; 102(3): 285-9, 2000 Jul 18.
Article in English | MEDLINE | ID: mdl-10899090

ABSTRACT

BACKGROUND-We determined whether repeated caffeine administration at different dosages and for different periods of time (400 or 600 mg/d for 1 week or 400 mg/d for 2 weeks) upregulates human platelet adenosine A(2A) receptors and is accompanied by increases in cAMP accumulation and decreases in aggregation and calcium levels after stimulation of A(2A) receptors by the selective agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine (HE-NECA). METHODS AND RESULTS-Platelets were obtained from peripheral venous blood of 45 healthy human volunteers at the end of 2 weeks of caffeine abstinence and at 12, 60, and 108 hours after the last dose of caffeine. The lowest dose of caffeine, when given for only 7 days, had no effect. Increasing the total dose, either by giving 400 mg/d for 14 days or giving 600 mg/d, resulted in binding assays performed with the adenosine A(2A) receptor radioligand [(3)H]SCH 58261 [5-amino-7(phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine], in the upregulation of A(2A) receptors. Moreover, the potency of HE-NECA to produce antiaggregatory effects, a rise in cAMP accumulation, and a decrease in calcium levels was significantly increased. CONCLUSIONS-Chronic caffeine intake can lead to upregulation of adenosine A(2A) receptors, which is accompanied by sensitization, in a time- and dose-dependent manner, to the actions of the agonist HE-NECA.


Subject(s)
Blood Platelets/metabolism , Caffeine/pharmacology , Receptors, Purinergic P1/blood , Adenosine-5'-(N-ethylcarboxamide)/analogs & derivatives , Adenosine-5'-(N-ethylcarboxamide)/pharmacology , Adult , Calcium/metabolism , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Myocardium/metabolism , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Purinergic P1 Receptor Agonists , Pyrimidines/metabolism , Receptor, Adenosine A2A , Receptors, Purinergic P1/physiology , Time Factors , Triazoles/metabolism , Up-Regulation
17.
J Med Chem ; 43(11): 2115-23, 2000 Jun 01.
Article in English | MEDLINE | ID: mdl-10841790

ABSTRACT

Various lines of evidence, including molecular modeling studies, imply that the endoethylenic bridge of 3,8-diazabicyclo[3.2. 1]octanes (DBO, 1) plays an essential role in modulating affinity toward mu opioid receptors. This hypothesis, together with the remarkable analgesic properties observed for N(3) propionyl, N(8) arylpropenyl derivatives (2) and of the reverted isomers (3), has prompted us to insert an additional endoethylenic bridge on the piperazine moiety in order to identify derivatives with increased potency toward this receptor class. In the present report, we describe the synthesis of the novel compounds 9,10-diazatricyclo[4.2. 1.1(2,5)]decane (4) and 2,7-diazatricyclo[4.4.0.0(3,8)]decane (5), as well as the representative derivatives functionalized at the two nitrogen atoms by propionyl and arylpropenyl groups (6a-e, 7a-d). Opioid receptor binding assays revealed that, among the compounds tested, the N-propionyl-N-cinnamyl derivatives 6a and 7a exhibited the highest mu-receptor affinity, and remarkably, compound 7a displayed in vivo (mice) an analgesic potency 6-fold that of morphine.


Subject(s)
Analgesics/chemical synthesis , Aza Compounds/chemical synthesis , Receptors, Opioid/metabolism , Analgesics/chemistry , Analgesics/metabolism , Animals , Aza Compounds/chemistry , Aza Compounds/metabolism , Binding, Competitive , Guinea Pigs , In Vitro Techniques , Male , Mice , Models, Molecular , Rats , Structure-Activity Relationship
18.
Mol Pharmacol ; 57(5): 968-75, 2000 May.
Article in English | MEDLINE | ID: mdl-10779381

ABSTRACT

The lack of a radiolabeled selective A(3) adenosine receptor antagonist is a major drawback for an adequate characterization of this receptor subtype. This paper describes the pharmacological and biochemical characterization of the tritiated form of a new potent A(3) adenosine receptor antagonist, the pyrazolo triazolo pyrimidine derivative [(3)H]5N-(4-methoxyphenylcarbamoyl)amino-8-propyl-2-(2-furyl )pyrazolo [4,3-e] -1,2,4- triazolo[1,5-c]pyrimidine ([(3)H]MRE 3008F20). [(3)H]MRE 3008F20 bound specifically to the human adenosine A(3) receptor expressed in CHO cells (hA(3)CHO), and saturation analysis revealed a single high affinity binding site, K(D) = 0.80 +/- 0.06 nM, with a B(max) = 300 +/- 33 fmol/mg protein. This new ligand displayed high selectivity (1294-, 165-, and 2471-fold) in binding assay to human A(3) versus A(1), A(2A), and A(2B) receptors, respectively, and binds to the rat A(3) receptors with a K(i) > 10 microM. The pharmacological profile of [(3)H]MRE 3008F20 binding to hA(3)CHO cells was evaluated using known adenosine receptor agonists and antagonists with a rank order of potency consistent with that typically found for interactions with the A(3) adenosine receptors. In the adenylyl cyclase assay the same compounds exhibited a rank order of potency identical with that observed in binding experiments. Thermodynamic data indicated that [(3)H]MRE 3008F20 binding to hA(3)CHO is entropy- and enthalpy-driven in agreement with the typical behavior of other adenosine antagonists to A(1) and A(2A) receptors. These results show that [(3)H]MRE 3008F20 is the first antagonist radioligand with high affinity and selectivity for the human A(3) adenosine receptor and may be used to investigate the physiopathological role of A(3) adenosine receptors.


Subject(s)
Phenylurea Compounds/pharmacology , Purinergic P1 Receptor Antagonists , Triazoles/pharmacology , Adenosine/analogs & derivatives , Adenosine/pharmacology , Adenylyl Cyclase Inhibitors , Animals , Binding, Competitive , CHO Cells , Cricetinae , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Humans , Phenylurea Compounds/chemistry , Radioligand Assay , Rats , Receptor, Adenosine A3 , Receptors, Purinergic P1/metabolism , Triazoles/chemistry , Tritium
19.
Bioorg Med Chem Lett ; 10(3): 209-11, 2000 Feb 07.
Article in English | MEDLINE | ID: mdl-10698437

ABSTRACT

The synthesis and the preliminary biological evaluation of the first high affinity radioligand antagonist for the human A3 adenosine receptor, named [3H]-MRE 3008-F20 are reported. [3H]-MRE 3008-20 bound human A3 receptors expressed in CHO cells with K(D) and Bmax value of 0.82 +/- 0.08 nM and 297 +/- 28 fmol/mg of protein, respectively. [3H]-MRE 3008-F20 represents a useful tool for a further characterization of A3 adenosine receptor subtype.


Subject(s)
Phenylurea Compounds/chemical synthesis , Phenylurea Compounds/pharmacology , Purinergic P1 Receptor Antagonists , Triazoles/chemical synthesis , Triazoles/pharmacology , Animals , CHO Cells , Cricetinae , Humans , Phenylurea Compounds/metabolism , Radioligand Assay , Receptor, Adenosine A3 , Receptors, Purinergic P1/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Triazoles/metabolism , Tritium
20.
J Hypertens ; 18(2): 217-21, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10694191

ABSTRACT

OBJECTIVE: Marked alterations have been demonstrated to occur in the platelet alpha2-adrenoceptors of patients with essential hypertension. The purpose of this study was to determine whether antihypertensive treatment with alpha-adrenergic blocker doxazosin or beta-adrenergic blocker propranolol can affect the affinity and the density of platelet alpha2-adrenoceptors in such patients. SUBJECTS AND METHODS: In two groups of 22 previously untreated, essential hypertensive patients, the mean affinity (Kd) and density (B(max)) of platelet alpha2-adrenoceptors were studied by [3H]-UK 14304 binding assays; the first assays were performed before any medication was begun, the second were performed after treatment for up to 13 weeks with doxazosin or propranolol. A third group of 22 healthy normotensive volunteers matched by age, sex and body mass index was used as control. RESULTS: Blood pressure did not differ significantly in the two hypertensive groups, and treatment with the two drugs resulted in closely similar, normal blood pressure levels. Kd and B(max) values were significantly higher in the two hypertensive groups than in controls. After treatment with propranolol the binding parameters did not change significantly, whereas after treatment with doxazosin Kd and B(max) returned to normotensive values. CONCLUSIONS: In previously untreated, essential hypertensive patients platelet alpha2-adrenoceptors have a lower affinity but a higher density than in normotensive subjects. Despite similar effects on blood pressure, the treatment with the alpha-adrenergic blocker doxazosin is followed by restoration of normal findings in the binding assays of platelet alpha2-adrenoceptors whereas the treatment with the beta-adrenergic blocker propranolol does not alter the Kd and B(max) values.


Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Blood Platelets/drug effects , Blood Platelets/metabolism , Doxazosin/therapeutic use , Hypertension/blood , Hypertension/drug therapy , Propranolol/therapeutic use , Receptors, Adrenergic, alpha-2/blood , Receptors, Adrenergic, alpha-2/drug effects , Adrenergic alpha-Agonists/metabolism , Brimonidine Tartrate , Case-Control Studies , Cell Membrane/metabolism , Female , Humans , In Vitro Techniques , Kinetics , Male , Middle Aged , Quinoxalines/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...